# A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

> **NCT00244244** · PHASE2 · COMPLETED · sponsor: **CytRx** · enrollment: 80 (—)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** arimoclomol

## Key facts

- **NCT ID:** NCT00244244
- **Lead sponsor:** CytRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 80 (—)
- **Last updated:** 2012-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244244, "A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00244244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*